Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

FDA Aims to Modernize 510(k) Device Program in Trio of Draft Guidances

  • Post author:PacConAdmin
  • Post published:September 6, 2023
  • Post category:Uncategorized

The FDA published three draft guidances Wednesday seeking to modernize the 510(k) pathway and help manufacturers navigate the premarket review process as medical devices become increasing complex and innovative. Source:…

Continue ReadingFDA Aims to Modernize 510(k) Device Program in Trio of Draft Guidances

Medtronic Sued for Disclosing HIPAA Protected PII and PHI to Google and Others

  • Post author:PacConAdmin
  • Post published:September 6, 2023
  • Post category:Uncategorized

Medtronic MiniMed has been accused of transmission and disclosure of HIPAA protected personally identifiable information (PII) and protected health information (PHI) from its InPen diabetes management system to Google, Crashlytics…

Continue ReadingMedtronic Sued for Disclosing HIPAA Protected PII and PHI to Google and Others

Meeting Planner — Sept. 4, 2023

  • Post author:PacConAdmin
  • Post published:September 6, 2023
  • Post category:Uncategorized

Upcoming events in the coming weeks include nine FDA advisory committee meetings as well as the GMP Quality Management vSummit, the WCG MAGI@Home Clinical Research Conference 2023, the 18th Annual…

Continue ReadingMeeting Planner — Sept. 4, 2023

Novartis Joins Fight Against IRA With Lawsuit Challenging Constitutionality

  • Post author:PacConAdmin
  • Post published:September 5, 2023
  • Post category:Uncategorized

Novartis has joined the chorus of pharma voices claiming the Inflation Reduction Act’s (IRA) Medicare Part D drug price negotiation provision exceeds Congress’s lawful authority. Source: Drug Industry Daily

Continue ReadingNovartis Joins Fight Against IRA With Lawsuit Challenging Constitutionality

Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

  • Post author:PacConAdmin
  • Post published:September 5, 2023
  • Post category:Uncategorized

Four major industry groups shared their thoughts on the International Council for Harmonization’s E6(R3) draft GCP guidelines, commenting on stakeholder engagement, diversity, service provider evaluations and pointing out areas that…

Continue ReadingMajor Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

Guidances Released on EPCIS Standard for DSCSA Compliance, Pulmonary Disease Drug Development

  • Post author:PacConAdmin
  • Post published:September 5, 2023
  • Post category:Uncategorized

The FDA recommends that “trading partners” use the Electronic Product Code Information Services (EPCIS) standard — developed by GS1 — for compliance with the Drug Supply Chain Security Act (DSCSA)…

Continue ReadingGuidances Released on EPCIS Standard for DSCSA Compliance, Pulmonary Disease Drug Development

Patient Engagement Adcomm Will Tackle CDRH Goals for Outpatient Device Access

  • Post author:PacConAdmin
  • Post published:September 5, 2023
  • Post category:Uncategorized

The Patient Engagement Advisory Committee (PEAC) — FDA’s only advisory committee comprised solely of patients, caregivers, and patient advocates — is seeking guidance on improving access to home-use medical devices…

Continue ReadingPatient Engagement Adcomm Will Tackle CDRH Goals for Outpatient Device Access

FDA Issues Guidances on Post-Warning Letter Meetings, Verification of Returned Drugs

  • Post author:PacConAdmin
  • Post published:September 1, 2023
  • Post category:Uncategorized

The FDA spells out the process for a generic drug facility to request a meeting to discuss deficiencies outlined in a warning letter, in a draft guidance released Friday. Source:…

Continue ReadingFDA Issues Guidances on Post-Warning Letter Meetings, Verification of Returned Drugs

$27.8 Billion Amgen and Horizon Merger Gets FTC Go-Ahead with Consent Order

  • Post author:PacConAdmin
  • Post published:September 1, 2023
  • Post category:Uncategorized

After dropping its challenge to the proposed transaction last week, the FTC will allow Amgen’s $27.8 billion buyout of Horizon Therapeutics to proceed under terms set in a consent order…

Continue Reading$27.8 Billion Amgen and Horizon Merger Gets FTC Go-Ahead with Consent Order

CDER Quality Management Maturity Meant to Support Quality Culture Mindset

  • Post author:PacConAdmin
  • Post published:September 1, 2023
  • Post category:Uncategorized

The FDA’s Center for Drug Evaluation and Research (CDER) seeks to dispel “possible misconceptions” about its proposed quality management maturity (QMM) system in a new white paper. Source: Drug Industry…

Continue ReadingCDER Quality Management Maturity Meant to Support Quality Culture Mindset
  • Go to the previous page
  • 1
  • …
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company